{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:15:44Z","timestamp":1780395344362,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["NIHR128210"],"award-info":[{"award-number":["NIHR128210"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Nutr"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Individuals receiving a standardised daily dose of 2000\u00a0mg of the\n                      <jats:italic>n<\/jats:italic>\n                      -3 highly unsaturated fatty acid (HUFA) eicosapentaenoic acid (EPA) for 12 months in the seAFOod polyp prevention trial demonstrated wide inter-individual variability in red blood cell (RBC) EPA levels (expressed as % of total measured fatty acids). Eicosapentaenoic acid can be converted to\n                      <jats:italic>n<\/jats:italic>\n                      -3 docosapentaenoic acid (\n                      <jats:italic>n<\/jats:italic>\n                      -3DPA) by the elongase\n                      <jats:italic>elongation of very long-chain fatty acids (ELOVL) 2<\/jats:italic>\n                      . We tested whether single nucleotide polymorphisms (SNPs) in\n                      <jats:italic>ELOVL2<\/jats:italic>\n                      (rs3734398, rs2236212, rs953413, rs3798713, rs9393903) are associated with differential RBC EPA and\n                      <jats:italic>n<\/jats:italic>\n                      -3DPA levels in seAFOod trial participants at baseline and while receiving EPA supplementation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six hundred and three seAFOod trial participants had\n                      <jats:italic>ELOVL2<\/jats:italic>\n                      genotype and RBC\n                      <jats:italic>n<\/jats:italic>\n                      -3 HUFA data. All five\n                      <jats:italic>ELOVL2<\/jats:italic>\n                      SNPs were in strong linkage disequilibrium (R\n                      <jats:sup>2<\/jats:sup>\n                      &gt; 0.95). Therefore, we focussed on rs953413 (genotype frequency: GG 30.8%, GA 50.1% and AA 19.1%), as the best characterised SNP, which is believed to be functional in human liver cells. Prior to trial intervention, minor (A) homozygotes displayed higher levels of\n                      <jats:italic>n<\/jats:italic>\n                      -3DPA (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), but not EPA (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05), in RBCs than major (G) allele carriers. The trend towards a greater increase in\n                      <jats:italic>n<\/jats:italic>\n                      -3DPA values in AA homozygotes during EPA treatment compared with GA heterozygotes or GG homozygotes did not reach statistical significance. There was also no significant difference in the change in RBC EPA or DHA levels during EPA treatment according to rs953413 genotype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A secondary analysis of the seAFOod trial found that minor (A allele) homozygotes for the\n                      <jats:italic>ELOVL2<\/jats:italic>\n                      SNP rs953413 have a higher baseline RBC\n                      <jats:italic>n<\/jats:italic>\n                      -3DPA level than G allele carriers. However, rs953413 genotype did not significantly influence \u0394EPA, \u0394\n                      <jats:italic>n<\/jats:italic>\n                      -3DPA, or \u0394DHA levels during 6 or 12 months of high-dose EPA supplementation. Therefore, we do not provide evidence that genetic variation in\n                      <jats:italic>ELOVL2<\/jats:italic>\n                      contributes to the inter-individual variability in the circulating EPA level associated with high-dose EPA supplementation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12263-026-00797-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:24:22Z","timestamp":1778750662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The relationship between elongation of very long-chain fatty acids (ELOVL) 2 polymorphism rs953413 and blood n-3 HUFA levels: a secondary analysis of EPA treatment in the seAFOod polyp prevention trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Ge","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Mell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha N. M.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda D.","family":"Race","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Loadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Minihane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/S0140-6736(18)31775-6","volume":"392","author":"MA Hull","year":"2018","unstructured":"Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial. Lancet. 2018;392:2583\u201394.","journal-title":"Lancet"},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.tjnut.2024.12.004","volume":"155","author":"G Sun","year":"2025","unstructured":"Sun G, Fuller H, Fenton H, Race AD, Downing A, Rees CJ, et al. The relationship between dietary and supplemental omega-3 HUFA intake, blood and tissue omega-3 HUFA levels, and colorectal polyp recurrence: A secondary analysis of the seAFOod polyp prevention trial. J Nutr. 2025;155:549\u201358.","journal-title":"J Nutr"},{"key":"797_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12263-024-00747-4","volume":"19","author":"I Loukil","year":"2024","unstructured":"Loukil I, Mutch DM, Plourde M. Genetic association between FADS and ELOVL polymorphisms and the circulating levels of EPA\/DHA in humans: a scoping review. Genes Nutr. 2024;19:11.","journal-title":"Genes Nutr"},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ajcnut.2024.06.004","volume":"120","author":"G Sun","year":"2024","unstructured":"Sun G, Li YN, Davies JR, Block RC, Kothapalli KSD, Brenna JT, et al. Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: A secondary analysis of the seAFOod polyp prevention trial. Am J Clin Nutr. 2024;120:360\u20138.","journal-title":"Am J Clin Nutr"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1158\/1940-6207.CAPR-23-0111","volume":"16","author":"JR Davies","year":"2023","unstructured":"Davies JR, Mell T, Fuller H, Harland M, Saleh RNM, Race AD, et al. Polymorphisms in Cyclooxygenase, Lipoxygenase and TP53 genes predict colorectal polyp risk reduction by aspirin in the seAFOod polyp prevention trial. Cancer Prev Res. 2023;16:621\u20139.","journal-title":"Cancer Prev Res"},{"key":"797_CR6","doi-asserted-by":"publisher","first-page":"100808","DOI":"10.1016\/j.isci.2019.100808","volume":"23","author":"G Pan","year":"2020","unstructured":"Pan G, Cavalli M, Carlsson B, Skrtic S, Kumar C, Wadelius C. rs953413 Regulates Polyunsaturated Fatty Acid Metabolism by Modulating ELOVL2 Expression. iScience. 2020;23:100808.","journal-title":"iScience"},{"key":"797_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3310\/eme06040","volume":"6","author":"MA Hull","year":"2019","unstructured":"Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, et al. Eicosapentaenoic acid and\/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy Mech Eval. 2019;6:4.","journal-title":"Efficacy Mech Eval"},{"key":"797_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jchromb.2017.04.030","volume":"1055\u20131056","author":"M Volpato","year":"2017","unstructured":"Volpato M, Spencer JA, Race AD, Munnarini A, Belluzzi A, Cockbain AJ, et al. A liquid chromatography-tandem mass spectrometry method to measure fatty acids in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1055\u20131056:125\u201334.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"797_CR9","first-page":"103","volume":"19","author":"JY Zhang","year":"2016","unstructured":"Zhang JY, Kothapalli KS, Brenna JT. Desaturase and elongase-limiting endogenous long-chain polyunsaturated fatty acid biosynthesis. Curr Opin Clin Nutr Metab Care. 2016;19:103\u201310.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"797_CR10","doi-asserted-by":"publisher","first-page":"e1000338","DOI":"10.1371\/journal.pgen.1000338","volume":"5","author":"T Tanaka","year":"2009","unstructured":"Tanaka T, Shen J, Abecasis GR, Kisialiou A, Ordovas JM, Guralnik JM, et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet. 2009;5:e1000338.","journal-title":"PLoS Genet"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"e000513","DOI":"10.1161\/JAHA.113.000513","volume":"2","author":"MR Flock","year":"2013","unstructured":"Flock MR, Skulas-Ray AC, Harris WS, Etherton TD, Fleming JA, Kris-Etherton PM. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. J Am Heart Assoc. 2013;2:e000513.","journal-title":"J Am Heart Assoc"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/ajcn\/nqz161","volume":"110","author":"RE Walker","year":"2019","unstructured":"Walker RE, Jackson KH, Tintle NL, Shearer GC, Bernasconi A, Masson S, et al. Predicting the effects of supplemental EPA and DHA on the omega-3 index. Am J Clin Nutr. 2019;110:1034\u201340.","journal-title":"Am J Clin Nutr"}],"container-title":["Genes &amp; Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12263-026-00797-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12263-026-00797-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12263-026-00797-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:31:05Z","timestamp":1780392665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12263-026-00797-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1186\/s12263-026-00797-w","relation":{},"ISSN":["1555-8932","1865-3499"],"issn-type":[{"value":"1555-8932","type":"print"},{"value":"1865-3499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}